ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C14H13NaO3
CAS番号:
分子量:
252.24
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
naproxen
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
[Na+].COc1ccc2cc(ccc2c1)[C@H](C)C([O-])=O
InChI
1S/C14H14O3.Na/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;/h3-9H,1-2H3,(H,15,16);/q;+1/p-1/t9-;/m0./s1
InChI key
CDBRNDSHEYLDJV-FVGYRXGTSA-M
Gene Information
human ... PTGS1(5742), PTGS2(5743)
General description
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
Application
Naproxen sodium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Naproxen Sodium and Pseudoephedrine Hydrochloride Extended-Release Tablets
- Naproxen Sodium Tablets
Biochem/physiol Actions
シクロオキシゲナーゼ(プロスタグランジHシンセターゼ1および2)インヒビターです。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under ナプロキセン ナトリウム
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 1A
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Arın Gül Dal et al.
Journal of analytical methods in chemistry, 2014, 352698-352698 (2014-10-09)
Simple and rapid capillary zone electrophoretic method was developed and validated in this study for the determination of piroxicam in tablets. The separation of piroxicam was conducted in a fused-silica capillary by using 10 mM borate buffer (pH 9.0) containing 10%
Jason A Miranda et al.
PloS one, 9(8), e106108-e106108 (2014-08-27)
Sensory processing in the spinal cord during disease states can reveal mechanisms for novel treatments, yet very little is known about pain processing at this level in the most commonly used animal models of articular pain. Here we report a
Matteo Morotti et al.
European journal of obstetrics, gynecology, and reproductive biology, 179, 63-68 (2014-06-27)
Evaluate patient satisfaction at 6-month treatment in women with symptomatic rectovaginal endometriosis and migraine without aura with (progestogen-only contraceptive pill, POP versus sequential combined oral contraceptives, COC) STUDY DESIGN: A patient preference trial including 144 women (82 in the group